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Accepted 3 December 2012AbstractObjective: The aim of our study was to assess the long-term efficacy of conservative surgery combined with gonadotropin-releasing hormone
agonist therapy for uterine adenomyoma.
Materials and Methods: We carried out an uncontrolled descriptive study of 285 women who had symptomatic uterine adenomyoma. A total of
186 women with pathologically proven adenomyoma underwent ultramini-laparoscopic adenomyomectomy and a 6-month course of goserelin
acetate treatment, and were evaluated semi-annually during a follow-up period of at least 3 years.
Results: Patient scores for dysmenorrhea using a self-reported six-point verbal numeric rating scale significantly declined compared with the
baseline assessment, from 3.84  0.65 to 0.33  0.57, 0.52  0.86, and 0.88  1.29 at the end of the 1-, 2-, and 3-year follow-up visits,
respectively ( p < 0.001). Similar reductions were observed for analgesic usage scores. Menorrhagia scores significantly decreased compared
with the baseline assessment, from 3.45  1.46 to 0.42  0.59, 0.65  0.83, and 1.1  1.34 at the end of the 1-, 2-, and 3-year follow-up visits,
respectively ( p < 0.001).
Conclusion: Combination therapy for adenomyoma provides an effective treatment option for long-term symptom control and uterine preser-
vation in severely symptomatic women for whom previous long-term drug therapy has failed or proven to be intolerable.
Copyright  2013, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Uterine adenomyoma is a gynecologic condition with
a diagnosis and a clinical significance that remain somewhat
enigmatic, and is most often associated with extensive-type
adenomyosis and endometriosis [1e6]. Hysterectomy is
a common surgical therapy for treating symptomatic adeno-
myoma. Various noninvasive diagnostic techniques, such as
ultrasonography and magnetic resonance imaging, allow ac-
curate diagnosis of adenomyosis in most cases [7,8]. The
recent advent of high-resolution transvaginal ultrasound
(TVUS) has markedly improved the accuracy of uterine* Corresponding author. Department of Obstetrics and Gynecology, Taipei
Medical University Hospital, Taipei, Taiwan.
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http://dx.doi.org/10.1016/j.tjog.2012.12.002adenomyoma diagnosis, with sensitivity ranging from 53% to
89%and specificity ranging from 65% to 98% [9e12]. How-
ever, the accuracy of TVUS in differentiating between leio-
myomas and adenomyoma may occasionally be limited
[7,10,13,14].
Conservative drug therapy for uterine adenomyoma in-
cludes the use of prostaglandin inhibitors, oral contraceptives,
progestogens, danocrine, and gonadotropin-releasing hormone
(GnRH) agonists [3,14e24]. However, the effects of these
medical treatments are often transient and the symptoms of
uterine adenomyoma, pain in particular, nearly always reap-
pear following cessation of the medication [1]. Surgical
treatments for uterine adenomyosis are effective in up to 50%
of patients [8,25e28]. However, follow-up assessments have
been of short duration, and the long-term effects of surgical
treatments are unclear [25e34].cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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drug therapy for the treatment of uterine adenomyoma by
combining ultramini-laparotomy with postoperative goserelin
acetate therapy. Our results show significant long-term
improvement in symptoms and preservation of the uterus in
patients with adenomyoma.
MethodsParticipantsOur study was approved by the Institutional Review Board
of Taipei Medical University Hospital. We reviewed female
patients between the ages of 18 and 55 years. Patients with
severe dysmenorrhea and/or menorrhagia were given a tenta-
tive diagnosis of uterine adenomyoma based on clinical and
TVUS findings. Patients were preoperatively excluded for
other diseases of the pelvic organs and illnesses that may
result in anemia to avoid confounding follow-up assessments.
Patients were excluded postoperatively on the following basis:
(1) negative pathological findings of adenomyoma; (2)
extensive uterine adenomyosis; (3) concurrent endometriosis;
or (4) other pelvic pathologies.Combined surgicaledrug treatmentUltramini-laparotomy was used for all the surgical pro-
cedures in our study [35e38]. The principles of reproductive
surgery were strictly followed, minimizing trauma to normal
uterine tissues at all times. The microsurgical technique was
applied using magnification, intermittent irrigation, and fine-
scale instrumentation to minimize blood loss and prevent
postoperative adhesion formation [39]. The adenomyotic le-
sions were resected and removal of all nonmicroscopic lesions
was assured by systematic and thorough palpation of the
uterus. The surgical margins were electrocauterized to destroy
all residual lesions and pelvic adhesions were excised. To
reduce bleeding, 10 mL of dilute vasopressin solution (20 U in
80 mL of isotonic sodium chloride solution) was administered
at the site of the adenomyoma.
For cases in which it was necessary to enter the uterine
cavity, 2-0 chromic sutures were used for closure. The tubal
ostia were visualized by inserting splints in both the uterine
cavity and the fimbriae to maintain patency [40] and a retro-
grade dye (methylene blue in saline solution) was injected to
demonstrate the os and prevent iatrogenic injury. Horizontal
sutures followed by locking sutures were used to close the
myometrium, leaving as little dead space as possible. The
serosa was closed with a continuous inverting suture of 5-
0 poliglecaprone 25 (Monocryl) to minimize raw surfaces on
the uterus. Finally, copious peritoneal irrigation with 1:10,000
heparin in lactate Ringer solution was used to remove debris
and blood clots from within the abdominal cavity [41].
All patients received a postoperative six-course monthly
regimen of 3.6 mg of goserelin acetate intramuscularly for
GnRH agonist therapy. The first dose was given to all partic-
ipants at the beginning of the first postoperative menstrualcycle. The GnRH agonist was administered postoperatively to
ensure intraoperative identification of adenomyotic lesions and
to suppress the postoperative progression of residual lesions.Assessment of treatment responseDysmenorrhea was defined as pelvic pain during, shortly
before, or after menstruation. Assessments of dysmenorrhea
were performed for the two menstrual periods immediately
preceding the time of the visit only. To evaluate variation in
pelvic pain, we used a self-reported six-point verbal numeric
rating scale (VNRS-6). Patients were asked to rate their pain on
a scale from0 to 5,with 0 representing no pain and 5 representing
the worst pain possible. The analgesic usage score (AUS) was
also recorded for analgesic use associated with menstrual pe-
riods according to the following criteria: 0, no analgesics needed;
1, occasional need for one or two doses of analgesic for less than
1 day; 2, need for more than three doses of analgesic for less than
3 days; 3, need for analgesic drugs during the entire menstrual
period; 4, need for analgesic drugs during the entire menstrual
period and occasionally on inter-menstruation days; and 5, need
for analgesic drugs on nearly every day.
Menorrhagia was defined as a persistent bleeding for more
than 7 days during each menstrual period combined with
hemoglobin of <10 g/dL in the absence of other causes of
anemia. Menorrhagia was graded on a five-point scale ac-
cording to menses duration and the degree of anemia as fol-
lows: 0, no anemia and menses for <4 days; 1, no anemia and
menses for 4e7 days; 2, no anemia and menses for >1 week;
3, anemia and menses for <4 days; 4, anemia and menses for
4e7 days; and 5, anemia and menses for >7 days.
Major complications were defined as any condition that
required further surgery or prolonged hospitalization. Patients
requiring additional procedures, such as blood transfusion,
were excluded regardless of whether the hospital stay was
compromised or additional surgery was required [42e45].
Patient satisfaction was scored on a three-point scale, with 1
representing dissatisfied, 2 representing satisfied, and 3 rep-
resenting very satisfied. Recurrence was defined as any
VNRS-6, AUS, or menorrhagia score  2 during follow-up.Follow-up proceduresFor a period of at least 3 years following completion of
GnRH agonist therapy, the participants’ menstrual symptoms,
including dysmenorrhea and menorrhagia, were assessed at 6-
month intervals. Satisfaction scores were also recorded at each
follow-up visit.Statistical analysisStatistical analysis was performed using SPSS software for
Windows, version 11.5 (SPSS Inc., Chicago, IL, USA). The
nonparametric paired sign test was used to evaluate changes in
scores compared with baseline data. The proportion of patients
suffering recurrence was determined by KaplaneMeier anal-
ysis using the log-rank test and stratified according to baseline
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considered to represent a statistically significant result.Fig. 1. Self-reported means for the six-point verbal numeric rating scale
(VNRS-6), the analgesic usage score (AUS), and menorrhagia grade assess-
ments significantly decreased during the follow-up period according to non-
parametric paired sign tests ( p < 0.001).Results
A total of 285 patients diagnosed with clinical symptoms
and TVUS findings associated with adenomyoma were
reviewed in our study. All patients underwent adenomyo-
mectomy without major complications or death following
surgery, and were followed up for as long as 77 months. We
excluded 92 patients because of the coexistence of other pelvic
diseases, including 29 patients with extensive uterine adeno-
myosis and 63 patients with endometriosis. An additional
seven patients (3.8%) who suffered from recurrent symptoms
were excluded because they underwent hysterectomy during
the follow-up period. The remaining 186 women (65.3%),
aged 21e51 years (mean 43.4 years), were included as par-
ticipants in our study.
The patient characteristics and baseline data for dysmenor-
rhea, AUS, and menorrhagia assessments are listed in Table 1.
Patient pain scores for dysmenorrhea significantly declined
compared with the baseline assessment (Fig. 1) from
3.84 0.65 to 0.33 0.57 at the end of the 1st year ( p< 0.001),
to 0.52  0.86 at the end of the 2nd year ( p < 0.001), and to
0.88  1.29 at the end of the 3rd year ( p < 0.001). The AUS
assessment results also decreased compared with baseline
measurements (Fig. 1) from2.39 1.16 to 0.22 0.46 at the end
of the first year ( p < 0.001), to 0.31  0.62 at the end of the
second year ( p < 0.001), and to 0.65  1.12 at the end of the
third year ( p< 0.001).Menorrhagia also improved significantly
compared with baseline scores (Fig. 1) from 3.45  1.46 to
0.42 0.59 at the end of the first year ( p< 0.001), to 0.65 0.83
at the end of the second year ( p< 0.001), and to 1.1 1.34 at the
end of the third year ( p < 0.001).
Consistent with the significant improvements in VNRS-6,
AUS, and menorrhagia assessments, no patients expressedTable 1
Clinical characteristics of the patients (n ¼ 186).
Parameter Result
Age (y) 43.4  8.3
Body mass index (kg/m2) 21.0  2.5
Parity
0 45 (24.2)
1 120 (64.5)
2 21 (11.3)
Baseline VNRS-6 3.8  0.7
Baseline analgesic usage score 2.4  1.2
Baseline menorrhagia scores 3.5  1.5
Anemia 133 (71.5)
Adenomyoma localization during surgery
Anterior 72 (38.7)
Posterior 98 (52.7)
Fundal 16 (8.6)
Adenomyoma entry into the uterine cavity 49 (26.3)
Data are expressed as mean  SD or n (%).
VNRS-6 ¼ self-reported six-point verbal numeric rating scale.dissatisfaction with the treatment modality at the 1-year
follow-up visit (Table 2). At the 2-year follow-up visit, more
than 90% of the patients (n ¼ 168) were very satisfied
(Table 2). However, two patients requested and subsequently
underwent hysterectomy because of the recurrence of symp-
toms. At the 3-year follow-up visit, 83.3% of the patients
(n ¼ 155) were still very satisfied and 8.1% were dissatisfied,
which included the two patients who had requested hysterec-
tomy at the second-year follow-up (Table 2). An additional
four patients requested hysterectomy at the 3-year follow-up
because of exacerbation of their dysmenorrhea and
menorrhagia.
There were no recurrences before the 18-month follow-up
visit. The cumulative proportion of patients with recurrence
during follow-up reached 1.8% at 36 months. The recurrence
rate at 36-month follow-up was 9% among patients with
baseline VNRS-6 scores of 3 or 4 and 66% for those with
a baseline VNRS-6 score of 5. The baseline AUS and men-
orrhagia grades showed a similar pattern. The rate of recur-
rence at 36-month follow-up was 70% among patients with
a baseline AUS score of 5, which was significantly higher than
for patients with baseline AUS scores of 0, 1, 2, 3, or 4, which
were 50%, 15%, 1%, 25%, and 33%, respectively, according
to the log rank test ( p < 0.001). Patients with a grade of 5 for
menorrhagia had a higher recurrence rate at 36-month follow-
up month (49%) compared to those with menorrhagia grades
of 1, 2, or 4, who had recurrence rates of 0%, 14%, and 10%,
respectively, according to the log rank test ( p < 0.001).Table 2
Satisfaction of women treated with combined surgicalemedical therapy dur-
ing follow-up after completion of gonadotropin-releasing hormone agonist
therapy.
Very satisfied Satisfied Dissatisfied
At the end of the first year 173 (93) 13 (7.0) 0 (0.0)
At the end of the second year 168 (90.3) 14 (7.5) 4 (2.2)
At the end of the third year 155 (83.3) 16 (8.6) 15 (8.1)
Data are presented as n (%).
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Strong evidence of decidual reactions in adenomyotic foci
combined with estrogen, progesterone, and androgen receptors
implies that ectopic endometrium is hormone-responsive,
suggesting a possible role for hormonal manipulation in the
treatment of adenomyoma [14]. Two studies used a progestin
levonorgestrel-releasing intrauterine device for management
of adenomyosis in women with menorrhagia [3,24,25].
Although high efficacy was reported, the authors acknowl-
edged that the side effects of prolonged exposure to progestin
treatment, such as headache, breast tenderness, seborrhea,
acne, and weight gain, may diminish long-term patient sat-
isfaction [24,25]. GnRH agonists may be better tolerated in
women receiving treatment for adenomyoma [14]. Treatment
with GnRH agonists results in both a reduction in uterine size
and symptomatic improvement. However, the effects of GnRH
agonist treatment are often transient, and treatment for longer
than 2 years is not recommended without adding hormone
therapy [19e22]. In addition, symptoms and signs will persist
in nearly all patients following cessation of therapy.
Relatively promising results for laparoscopic electro-
surgical myolysis in patients with adenomyosis were described
in a small cohort by Phillips et al [29], in which seven of 10
women treated with three courses of GnRH agonist following
myolysis continued to have complete resolution or sig-
nificantly reduced symptoms at 12 months following surgery
[29]. Wood et al reported that four of seven women treated
experienced prolonged symptom relief [28], and that seven of
eight women who underwent myometrial resection for local-
ized adenomyosis experienced long-term reductions in both
menorrhagia and dysmenorrhea [1,28].
Conservative surgical approaches, such as laparoscopic
excision of myometrial adenomyomas, have had variable re-
sults [5,6,8,31,32]. These surgical approaches produced short-
term relief of symptoms in only 64% of patients, and only 55%
of patients were symptom-free at 24 months following surgery
[1,3], suggesting that the efficacy of these methods is limited.
Thus, combinations of surgery and drug therapy are worthy of
evaluation. Our data show that combination therapy resulted in
dramatically improved efficacy, with more than 90% of our
study patients reporting that they were very satisfied at the 2-
year follow-up visit and over 83% reporting that they were
very satisfied at the 3-year follow-up visit.
Because conservative surgical approaches are often inef-
fective for the treatment of uterine adenomyomas, hysterec-
tomy may represent the only feasible solution in many cases
[46]. A total of seven of our patients (3.8%) suffered recur-
rent symptoms and underwent hysterectomy during follow-up.
However, previous studies of surgery alone reported a less
than 70% improvement in symptoms at 24 months following
surgery, and drug therapy alone did not result in permanent
symptom improvement [1,3]. By contrast, more than 80% of
the patients in our study reported being very satisfied with
their level of symptom improvement at 36 months following
treatment with combination surgeryedrug therapy for the
management of adenomyoma.One limitation to the findings of our study is that TVUS
was not used to evaluate patients at every visit. Thus, our
assessment of the recurrence of adenomyoma was not clin-
ically definitive. However, the final diagnosis of uterine ade-
nomyoma is always retrospective, and our use of the VNRS-6,
AUS, and menorrhagia grade assessments as indicators of the
symptoms of recurrence during follow-up provide substantial
clinically relevant information.
In conclusion, our results indicate that conservative surgery
combined with adjuvant GnRH agonist drug therapy in the
treatment of adenomyoma is efficacious in controlling symp-
toms, resulting in a high satisfaction rate among patients and
a high success rate for preservation of the uterus for at least 3
years. Because the surgery component is an invasive proce-
dure, this combination therapy may not be appropriate for all
patients and should be limited to preserving the uterus in
severely symptomatic women with adenomyosis for whom
long-term drug therapy has failed or has proven to be intol-
erable. Additional long-term studies of similar surgeryedrug
combination treatment for adenomyoma are warranted to
verify our findings.Acknowledgments
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